Jerome Carle

Jerome Carle has extensive experience in finance and leadership roles in various industries. Jerome currently serves as the CFO at Silal, a company with investments in various sectors. Their responsibilities include corporate finance, financial planning, accounting, reporting, and treasury management. Jerome also drives investments and M&A activities and supports strategic initiatives.

Prior to their current role, Carle was a Board Member and Audit Committee Chairman at Pharmax Pharmaceuticals FZ LLC. Jerome advised the management team and shareholders, ensured financial compliance, and facilitated the merger with ACINO.

Carle also has experience in consulting, having worked as the CFO and Managing Director at JLC Consulting & Services. Jerome supported a private equity asset manager in East Africa and served as interim CFO for a fintech start-up in West Africa. Jerome also worked on multiple M&A projects in the MENA region.

Earlier in their career, Carle held the positions of CFO and CEO at Julphar, a pharmaceutical manufacturer and distributor, where they led the management team and reported to the Board of Directors. Jerome also served as Chairman of the Board at Gulf Inject, a company specializing in IV fluids.

Carle began their career at Sanofi, where they spent 17 years in various finance roles, including CFO, Head of Finance, and Senior Internal Auditor. Jerome also worked at Ford Motor Company and PSA Peugeot Citroën in finance roles.

Overall, Carle's work experience showcases their expertise in finance, leadership, strategic planning, and mergers and acquisitions in the pharmaceutical and other industries.

Jerome Carle has a Master Degree in Economy and Management from KEDGE Business School, which they completed from 1996 to 1999. Before that, they attended Notre Dame des Minimes in Lyon, France, where they pursued Classe Prépa HEC from 1994 to 1995. In terms of professional development, they undertook various short-term programs in negotiation dynamics at INSEAD in 2017, change management at Harvard Business School in 2016, corporate governance and board effectiveness at IMD starting in 2022, a mentoring program at London Business School in 2021, and private equity studies at Università Bocconi in 2020.